Date
Title
May 15, 2018
NIAID Sponsors ILiAD Biotechnologies BPZE1 Pertussis Vaccine Phase 2a Clinical Study at Vanderbilt University
July 5, 2017
ILiAD Biotechnologies BPZE1 Pertussis Vaccine Reaches Key Milestones Including Positive Phase 1b Clinical Study Data
February 19, 2016
Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups
January 8, 2014
ILiAD Biotechnologies, Inserm and Inserm Transfert SA, and Institut Pasteur de Lille Enter Scientific Collaboration and Worldwide License Agreements for Vaccine Technology
